Revised Schedule M Explained: A Summary for Pharma Freshers

In short: Schedule M to the Drugs Rules, 1945 sets out India’s Good Manufacturing Practice requirements. It was substantially revised by notification G.S.R. 922(E) dated 28 December 2023, bringing Indian GMP closer to international expectations, with a pharmaceutical quality system, quality risk management, product quality reviews, stronger validation and better documentation. This summary explains the main themes in plain language so freshers can answer interview questions and understand why plants are changing their procedures.

What Schedule M is

Schedule M is part of the Drugs Rules, 1945, made under the Drugs and Cosmetics Act, 1940. Its full title is Good Manufacturing Practices and Requirements of Premises, Plant and Equipment for Pharmaceutical Products, and it sets out what licensed drug manufacturers in India must follow. State licensing authorities and the Central Drugs Standard Control Organisation (CDSCO) inspect manufacturers against it.

Before the revision, many Indian plants that exported to regulated markets already worked to stricter standards, such as WHO GMP, EU GMP or US FDA requirements. Many domestic-focused manufacturers, especially smaller units, worked to the older Schedule M. The revision narrows that gap.

Why it was revised

The revised Schedule M aims to align Indian GMP more closely with internationally recognised GMP. This supports quality consistency across all manufacturers, not only exporters. For a fresher, the practical message is simple: plants are expected to run a documented, risk-based quality system, not just meet premises and equipment checklists.

Key themes of the revised Schedule M

The revised text is long. Part I sets out the main GMP principles in 20 sections, from the pharmaceutical quality system (section 1) and quality risk management (section 2) to computerised systems (section 20). Parts II to XII add requirements for specific product types, and Part XIII lists plant and equipment requirements. The themes below are the ones freshers are most often asked about, with the matching Part I section in brackets.

1. Pharmaceutical quality system (PQS) (section 1)

Manufacturers are expected to have a pharmaceutical quality system that covers the full product lifecycle: management responsibility, quality policy, resources, and continual improvement. This idea is closely aligned with ICH Q10, which describes four PQS elements: process performance and product quality monitoring, CAPA, change management, and management review. Our article on ICH Q10 PQS elements explains these in more detail.

2. Quality risk management (QRM) (section 2)

Decisions about quality, such as investigation depth, monitoring frequency or the impact of a change, should be based on a documented assessment of risk to the patient. The approach mirrors ICH Q9(R1). See our quality risk management explainer.

3. Product quality review (PQR) (section 2.3)

Manufacturers must carry out regular quality reviews of every product, including products made only for export. These reviews are normally conducted and documented annually for consistency of the process, specifications, deviations, changes, complaints, stability and trends. Many plants call this the APQR. Our APQR example SOP shows what such a review contains.

4. Qualification and validation (section 5)

There is a stronger emphasis on qualifying equipment, facilities and utilities, validating processes, cleaning and analytical methods, and keeping them in a validated state through change control and periodic review.

5. Computerised systems and data integrity (section 20)

GMP-related computerised systems, such as chromatography data systems, LIMS and equipment controllers, must be validated. Schedule M also asks for controls against unauthorised access or changes to data, a record of every data change (previous entry, who changed it and when), change control and back-up so that records are not lost. These controls support data integrity, which many companies describe with ALCOA+ principles.

6. Complaints, recalls, deviations and CAPA (sections 6 to 8)

Systems for handling complaints and product recalls, investigating deviations and failures, and tracking CAPA must be defined and effective.

7. Supplier and vendor control (sections 10 and 14)

Starting and packaging material suppliers must be approved and monitored, and starting materials are to be bought only from approved suppliers. Our vendor management SOP shows a typical approach.

8. Stability and quality control (sections 15 and 19)

QC laboratory practices, stability programmes, reference standards and retention samples must meet defined requirements. For example, retention samples from each batch of finished product are kept for at least one year after the expiry date.

9. Product-specific requirements

Beyond the general requirements in Part I, the revised Schedule M has specific parts for different product types:

Part II: sterile products (including small volume injectables and large volume parenterals)
Part III: products containing hazardous substances, such as sex hormones, steroids and cytotoxic substances
Part IV: biological products
Part V: radiopharmaceuticals
Part VI: phytopharmaceuticals
Part VII: investigational products for clinical trials in humans
Part VIII: oral solid dosage forms (tablets and capsules)
Part IX: oral liquids (syrups, elixirs, emulsions and suspensions)
Part X: topical products (external preparations)
Part XI: metered dose inhalers (MDI)
Part XII: active pharmaceutical ingredients (APIs)
Part XIII: requirements of plant and equipment

Our article on oral solid dosage manufacturing under Schedule M covers one of these.

Who must comply, and by when

The revised Schedule M applies to manufacturers licensed under the Drugs Rules. G.S.R. 922(E) set two implementation timelines based on annual turnover:

Category of manufacturer	Timeline in G.S.R. 922(E)
Large manufacturers (turnover above ₹250 crore)	Six months from the date of publication of the rules
Small and medium manufacturers	Twelve months from the date of publication of the rules

The Drugs Amendment Rules, 2025 (G.S.R. 127(E), 11 February 2025) then allowed small and medium manufacturers to seek more time. Those who applied to the central licensing authority in Form A, with a gap analysis and a plan of upgradation, could have their timeline extended up to 31 December 2025. That extended deadline has now passed, so the revised Schedule M is expected to be in place at all licensed manufacturers.

For freshers, the key point is that compliance is not optional and inspections check it. If you join a plant that is upgrading, you may see new SOPs, new forms, risk assessments and qualification work. This is the revised Schedule M at work.

Old vs revised Schedule M: what feels different on the shop floor

Area	What many plants did before	What the revised approach expects
Quality system	Separate procedures, often checklist-driven	An integrated PQS with management review and continual improvement
Risk	Decisions often based on experience alone	Documented, risk-based decisions (QRM)
Product review	Not always done formally	Regular product quality review with trend analysis
Validation	Limited to key processes	Qualification and validation across equipment, utilities, processes, cleaning and methods
Data	Paper-heavy, weak control of electronic data	Controlled computerised systems with audit trails
Vendors	Approved lists with limited review	Qualified and monitored suppliers

This table shows typical differences in practice; individual plants vary.

What this means for a fresher’s daily work

More documentation and more discipline. Expect detailed SOPs, logbooks and batch records, and strict good documentation practice.
Risk assessments are common. You may be asked to contribute to FMEA-type assessments for changes or deviations.
Data integrity matters. Your user ID, password and signatures are personal, and audit trails record your actions.
Training is continuous. New or revised SOPs come with training, and records of that training are checked in audits.
Quality is everyone’s job. Production, QC, engineering and warehouse staff all have GMP responsibilities, not only QA.

How to answer interview questions on revised Schedule M

Q: What is Schedule M? A: It is the part of the Drugs Rules, 1945 that sets GMP and premises, plant and equipment requirements for drug manufacturers in India. It was revised by G.S.R. 922(E) on 28 December 2023.

Q: What are the main changes in the revised Schedule M? A: It introduces a pharmaceutical quality system, quality risk management, product quality review, stronger qualification and validation, control of computerised systems, and better handling of complaints, recalls and CAPA. Overall, it aligns Indian GMP more closely with international GMP.

Q: How does it relate to WHO GMP or ICH Q10? A: The concepts are closely aligned. The revised Schedule M adopts many of the same principles, such as PQS and QRM, that are found in WHO GMP and ICH Q9 and Q10.

Keep your answers general unless you have read the official text. Interviewers respect accurate, honest answers more than invented details.

Key terms freshers should know

Term	Plain-language meaning
Pharmaceutical quality system (PQS)	The management system that directs and controls a company’s quality activities across the product lifecycle
Quality risk management (QRM)	A systematic way to assess, control, communicate and review risks to product quality
Product quality review (PQR / APQR)	A regular review of each product’s data to confirm consistency and find improvements
Qualification	Proving that equipment, utilities or facilities are installed and work correctly (DQ, IQ, OQ, PQ)
Validation	Proving that a process, cleaning procedure or analytical method consistently gives the expected result
CAPA	Corrective and preventive action to remove the cause of a problem and stop it recurring
Change control	A formal system to assess, approve and track changes before they are implemented
Data integrity	Data that is complete, consistent and accurate throughout its lifecycle (ALCOA+)

How a plant typically prepares for the revised requirements

Every company does this differently, but many follow a pattern like this (an example in-house approach, not a regulatory requirement):

Gap assessment: compare current procedures and facilities with the revised Schedule M and list the gaps.
Risk-based prioritisation: fix the gaps with the highest patient risk first, such as contamination control, data integrity or validation.
Action plan: assign owners, timelines and budgets, tracked through change control and CAPA.
Document updates: revise SOPs, create new ones for PQS, QRM and PQR, and train staff.
Facility and equipment work: upgrade premises, HVAC, water systems or equipment where needed, followed by qualification.
Self-inspection: check progress internally before regulatory inspections.

As a fresher, you may help with document updates, training records, qualification paperwork or data collection for product reviews. This is excellent experience, because it shows you how a complete quality system is built.

Frequently asked questions

Where can I read the official revised Schedule M?

The official notification G.S.R. 922(E) dated 28 December 2023 is published in the Gazette of India (egazette.gov.in). CDSCO lists it, its corrigendum (G.S.R. 666(E), 25 October 2024) and the extension notification G.S.R. 127(E) under Gazette Notifications on cdsco.gov.in. CDSCO also publishes a compiled version of the Drugs Rules, 1945.

Does the revised Schedule M apply to export-oriented plants?

Yes. It applies to licensed manufacturers in India. Export plants must also meet the requirements of the importing country’s regulator.

Is WHO GMP the same as Schedule M?

No. They are separate documents, but the revised Schedule M is broadly aligned with WHO GMP principles.

Do freshers need to read the whole Schedule M?

Not the whole text at first. Understand the main themes and read the sections that apply to your department and product type.

References

Ministry of Health and Family Welfare, Government of India. G.S.R. 922(E), 28 December 2023: rules further to amend the Drugs Rules, 1945, substituting Schedule M (Good Manufacturing Practices and Requirements of Premises, Plant and Equipment for Pharmaceutical Products). Gazette of India, Extraordinary, Part II, Section 3(i).
Ministry of Health and Family Welfare, Government of India. G.S.R. 666(E), 25 October 2024: corrigendum to G.S.R. 922(E).
Ministry of Health and Family Welfare, Government of India. G.S.R. 127(E), 11 February 2025: Drugs Amendment Rules, 2025 (extension of timeline for small and medium manufacturers, Form A).
Government of India. The Drugs and Cosmetics Act, 1940.
ICH. Q9(R1) Quality Risk Management (2023).
ICH. Q10 Pharmaceutical Quality System (2008).